Posts

MBTAAnalysis: A look inside the MBTA

/
The MBTA shuttles over a million passengers a day around Greater…

The Clock is Ticking…….

/
The clock is ticking towards December 30, 2017.  As part of…

Targeting Pharma: Infrastructure Bill Employs Price Controls To Offset Unprecedented Price Tag

Hubwonk host Joe Selvaggi talks with Pioneer Institute Visiting Fellow in Life Sciences Dr. William Smith about how the price control features of the emerging $3.5 trillion infrastructure bill might affect the pharmaceutical Industry, both nationwide and here in Massachusetts, and what effect that change will have on drug consumers.

A Rush to Judgment on Alzheimer’s Drug

/
The Boston-based Institute for Clinical and Economic Review (ICER) sells itself as an independent source of information on the value of pharmaceuticals. But earlier this month, their bias was again evident when they tried to kneecap a drug for a dreaded disease before there’s even enough data to determine how valuable the drug really is. ICER has adopted this same strategy in the past on innovative drugs for cancer, cystic fibrosis, and other devastating diseases. This time ICER’s target is aducanumab, Biogen’s drug for Alzheimer’s disease.

Study: Growing Drug Rebates Hurt Both Consumers and Healthcare System

Ever-larger rebates are distorting the market for branded drugs and producing outcomes that often benefit neither consumers nor the healthcare system, according to a new study published by Pioneer Institute.

Survey Finds Prescription Drug Prices Easy To Access, But Not Always Accurate

Wide variation found in price of generics, less for brand-name…

Study: Are Drug Prices Driving Healthcare Cost Growth?

Study: Requiring Drug Companies to Disclose Price Methodologies,…